Inovio Pharmaceuticals, Inc. financial data

Symbol
INO on Nasdaq
Location
660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 10, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 169 % -58.6%
Debt-to-equity 141 % +238%
Return On Assets -128 % -53.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 53.6M shares +105%
Common Stock, Shares, Outstanding 53.6M shares +106%
Entity Public Float 208M USD +73.8%
Common Stock, Value, Issued 53.6K USD +106%
Weighted Average Number of Shares Outstanding, Basic 52.2M shares +85.4%
Weighted Average Number of Shares Outstanding, Diluted 52.2M shares +85.4%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 182K USD -10.4%
Research and Development Expense 56.8M USD -29%
General and Administrative Expense 33.1M USD -16.6%
Operating Income (Loss) -89.7M USD +24.9%
Net Income (Loss) Attributable to Parent -108M USD +4.24%
Earnings Per Share, Basic -2 USD/shares +42.8%
Earnings Per Share, Diluted -2 USD/shares +42.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 36.6M USD +68.6%
Cash, Cash Equivalents, and Short-term Investments 50.8M USD -40.1%
Accounts Receivable, after Allowance for Credit Loss, Current 979K USD -47.5%
Assets, Current 55.2M USD -39.6%
Property, Plant and Equipment, Net 2.74M USD -33%
Operating Lease, Right-of-Use Asset 6.96M USD -17.9%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Goodwill 0 USD -100%
Other Assets, Noncurrent 2.01M USD +255%
Assets 69.4M USD -35.2%
Liabilities, Current 69.8M USD +197%
Deferred Income Tax Liabilities, Net 0 USD -100%
Operating Lease, Liability, Noncurrent 7.28M USD -27.3%
Liabilities 77.1M USD +130%
Accumulated Other Comprehensive Income (Loss), Net of Tax -647K USD -3.83%
Retained Earnings (Accumulated Deficit) -1.82B USD -6.32%
Stockholders' Equity Attributable to Parent -7.72M USD -110%
Liabilities and Equity 69.4M USD -35.2%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26.9M USD +6.56%
Net Cash Provided by (Used in) Financing Activities 1.03M USD
Net Cash Provided by (Used in) Investing Activities -51.8K USD -100%
Common Stock, Shares Authorized 600M shares 0%
Common Stock, Shares, Issued 53.6M shares +106%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -25.9M USD -589%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 36.6M USD +68.6%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 349M USD +6.64%
Deferred Tax Assets, Gross 351M USD +6.51%
Operating Lease, Liability 10M USD -19.5%
Depreciation 371K USD -12.5%
Payments to Acquire Property, Plant, and Equipment 59.4K USD +66.9%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -108M USD +4.11%
Lessee, Operating Lease, Liability, to be Paid 11.9M USD -22.1%
Property, Plant and Equipment, Gross 20.1M USD -22%
Operating Lease, Liability, Current 2.74M USD +12.9%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.99M USD -15.8%
Lessee, Operating Lease, Liability, to be Paid, Year One 3.59M USD +3.13%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.9M USD -33.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.32M USD -21.5%
Deferred Tax Assets, Operating Loss Carryforwards 250M USD +6.24%
Preferred Stock, Shares Issued 9 shares 0%
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 24.6M USD +11.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.13M USD -7.71%
Additional Paid in Capital 1.81B USD +1.5%
Preferred Stock, Shares Outstanding 9 shares 0%
Amortization of Intangible Assets 0 USD -100%
Deferred Tax Assets, Net of Valuation Allowance 1.7M USD -14.5%
Interest Expense 1.09M USD -13.3%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%